Department of hematology and chemotherapy with an intensive care unit
The Department of Hematology and Chemotherapy with an Intensive Care Unit provides specialist and high-tech medical care to patients with lymphomas, multiple myeloma and acute leukemia. To treat its patients, the Department uses intensive and high-dose chemotherapy and bone-marrow transplantation.
The Department of Hematology and Chemotherapy with an Intensive Care Unit was established in 1965. Over the past 50 years of its history, the Department’s research and treating activities have been focused on using chemotherapy to treat patients with all types of malignant tumors, paying special attention to the treatment of lymphomas.
Medical care offered to patients with lymphomas and leukemia at the N.N. Petrov National Medical Research Center of Oncology includes:
- Histologic diagnosis, using immunophenotyping (flow cytophotometry, immunohistochemistry) and genetic analysis
- Staging based on bone marrow biopsy, endoscopy, computed tomography and other types of modern techniques of diagnostic radiology
- Standard chemotherapy, including target drugs and monoclonal antibodies
- High-dose chemotherapy and autologous bone marrow transplantation (autologous=patient’s own)
- Allogeneic bone marrow transplantation (allogeneic=donor, who is either a relative or an unrelated person)
The Department uses the following modern treatment options:
- Drug anti-tumor therapy (including target drugs and immunotherapy drugs) and bone marrow transplantation for patients with lymphomas and other malignancies of lymphoid and hematopoietic tissue, and for patients with solid tumors of different histogenesis (origin of tissues)
- Standard and intensive anticancer chemotherapy in conjunction with immunotherapy
-
High-dose anticancer chemotherapy with autologous bone marrow transplantation (hematopoietic stem cells from peripheral blood)
- as part of the initial therapy in cases of aggressive lymphomas
- in cases of progression of lymphomas during the initial conventional therapy
- in cases of recurrences of lymphomas as part of the conventional anticancer therapy of plasma cell myeloma
- Allogeneic bone marrow transplantation (from a donor who is either a relative (fully compatible and haploidentical) or an unrelated person
- Follow-ups with patients who have undergone treatment at the Department
- Collection, preparation, cryopreservation and storage of bone marrow (hematopoietic stem cells from peripheral blood)
- Treatment of complications of drug anticancer therapy and bone marrow transplantation
Special attention is paid to:
- the use of modern drug treatment regimens based on molecular genetic testing, morphological examination and immunohistochemistry assays;
- the use of targeted therapy;
- a wide use of high-dose chemotherapy with bone marrow transplantation as part of treatment plans;
- allogeneic bone marrow transplantation.
The Department performs modern high-dose anticancer chemotherapy:
- standard chemotherapy (CHOP-R, EPOCH-R, BEACOPP, VCD, etc.)
- intensive chemotherapy (Hyper-CVAD, DHAP, ICE, methotrexate and cytarabine in high doses);
- high-dose anticancer chemotherapy (BEAM, melphalan) in conjunction with allogeneic hematopoietic stem cell transplantation.
High-dose anticancer chemotherapy in conjunction with allogeneic hematopoietic stem cell transplantation is indicated:
- for treatment of some cases of aggressive lymphomas as part of the initial therapy;
- in cases of disease progression during the initial conventional therapy of lymphomas;
- for treatment of recurring lymphomas;
- as part of conventional anticancer therapy of plasma cell myeloma.
Allogeneic bone marrow transplantation (from a donor who is either a relative (fully compatible and haploidentical) or an unrelated person.
The Department is headed by Dr Ilya S. Zyuzgin.
Established more than 50 years ago, the Department has become one of the leading facilities for the diagnosis and treatment of lymphoproliferative diseases.
The Department specializes in providing chemotherapy treatment for patients with lymphomas, plasma cell myeloma and acute leukemia.